Senior Global Access Evidence Leader - EU HTA Statistician

Shape Roche's EU HTA evidence strategy by driving innovative evidence packages and ensuring alignment with EMA regulations. This role is for a visionary leader with extensive EU HTA expertise and advanced statistical skills, passionate about advancing evidence standards and supporting patient access across Europe.

At Roche, you are embraced for your unique qualities. The culture encourages personal expression, open dialogue, and genuine connections, allowing you to thrive both personally and professionally. Roche aims to prevent, stop, and cure diseases and ensure access to healthcare for everyone today and for generations to come.

• Lead EU HTA evidence strategy by embedding sophisticated, anticipatory evidence strategies into clinical development from inception, ensuring alignment with EMA regulations and new EU HTA regulations.
• Drive methodological innovation in EU contexts by leveraging established networks within European HTA bodies, payers, and health authorities to advance evidence standards and best practices.
• Design innovative, region-specific evidence packages that anticipate the needs of EMA committees, HTA bodies, and national payers.
• Identify strategic evidence gaps early, pioneer novel data sources and analyses, and translate complex statistical findings into narratives that drive reimbursement and access decisions across EU markets.
• Leverage reputation and deep relationships within the European Access/HTA ecosystem to elevate submission quality, engage proactively with key opinion leaders and HTA bodies, and position Roche as a thought leader in EU evidence generation and submission strategy.
• Lead and critically evaluate complex statistical analyses—including network meta-analyses and real-world evidence syntheses—ensuring methodological rigor and compliance with EU HTA requirements while translating findings into compelling, region-appropriate narratives.
• Guide European affiliate teams and cross-functional partners in building robust EU submission strategies, ensure alignment across EMA development pathways and national HTA submissions, and mentor colleagues on evolving EU regulatory and HTA landscapes.
• Maintain influential engagement with European HTA bodies, regulatory agencies, and academic networks—actively participating in professional forums, contributing to methodological debates, and ensuring Roche remains at the forefront of EU evidence standards and innovation.